Trial Profile
A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Vascular Endothelial Growth Factor (VEGF) Driven Choroidal Neovascularization
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Registrational; Therapeutic Use
- Acronyms MINERVA
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 06 Feb 2019 Outcomes of a patient-level simulation model assessing cost-effectiveness in UK of intravitreal ranibizumab compared with best supportive care using patient-level data from this trial, were published in the Advances in Therapy Journal.
- 01 Aug 2018 Results published in the Retina
- 07 Dec 2016 Results published in the Novartis Media Release.